Scientific Publications

Dr. S.R. Burzynski and his associates continuously report new scientific information. The following is a list of publications that excludes articles published before 2010.

 Targeted Therapy

  • Burzynski, S.R., Burzynski, G.S., Brookman, S. A case of sustained objective response of recurrent/progressive diffuse intrinsic pontine glioma with phenylbutyrate and targeted agents. J Cancer Ther 2015;6:40-44.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Brookman, S. Preliminary findings on the use of targeted therapy with pazopanib and other agents in combination with sodium phenylbutyrate in the treatment of glioblastoma multiforme. J Cancer Ther 2014;5:1423-1437.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Brookman, S. Preliminary findings on the use of targeted therapy in combination with sodium phenylbutyrate in colorectal cancer after failure of second-line therapy – A potential strategy for improved survival. J Cancer Ther 2014;5:1270-1288.
  • Burzynski, S.R., Burzynski, G.S. Long-term progression-free survival of recurrent glioblastoma multiforme treated with a combination of targeted agents: A case report. AT-14. Neuro Oncol 2014;16(Suppl. 5):v11.Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Brookman, S.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Brookman, S. Preliminary findings on the use of targeted therapy in combination with sodium phenylbutyrate in recurrent advanced pancreatic cancer – A potential strategy for improved survival. J Cancer Ther 2014;5:1072-1091.
  • Burzynski, S.R., Burzynski, G.S., Janicki, T.J. Recurrent glioblastoma multiforme, a strategy for long-term survival. J Cancer Ther 2014;5:957-976.
  • Burzynski, S.R, Nagy-Kubove, E.Treatment of esthesioneuroblastoma and non-small cell lung cancer with phenylbutyrate. Journal of Cancer Therapy 2011;2:518-522.
  • Burzynski S.R., Janicki T. J., Beenken S, Treatment of Recurrent Glioblastoma Multiforme (RGBM) with Antineoplaston AS2-1 In Combination With Targeted Therapy Cancer in Clinical Oncology 2019;8:1-15

Clinical Trials

  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S. A phase II study of antineoplastons A10 and AS2-1 in adult patients with recurrent anaplastic astrocytoma. Final report (Protocol BT-15). Cancer ClinOncol 2015; 442) : 13-23 in press.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 in patients with brainstem gliomas. The report on non-diffuse intrinsic pontine glioma (Protocol BT-11). J Cancer Ther 2015;6:334-344.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 in adult patients with newly-diagnosed anaplastic astrocytoma. Final report (Protocol BT-08). Cancer ClinOncol 2015;4(1):28-38.
  • Burzynski, S.R., Janicki, T.J., Marszalek, A., Burzynski, G.S. A phase II study of antineoplastons A10 and AS2-1 in patients with brainstem gliomas final report (Protocol BT-11). AT-15. Neuro Oncol 2014;16(Suppl. 5):v11.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S. A phase II study of antineoplastons A10 and AS2-1 in adult patients with recurrent glioblastoma multiforme. Final report (Protocol BT-21). J Cancer Ther 2014;5:946-956.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A., Brookman, S. A phase II study of antineoplastons A10 and AS2-1 in children with recurrent, refractory or progressive primary brain tumors. Final report (Protocol BT-22). J Cancer Ther 2014;5:977-988.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 in children with high-grade glioma. Final report (Protocol BT-06), and review of recent trials. J Cancer Ther 2014;5:565-577.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma. Child’s Nervous System 2014;30(12):2051-2061.
  • Burzynski, S.R., Janicki, T., Burzynski, G., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 in children with recurrent, refractory or progressive primary brain tumors based on protocol BT-22. CT-004. Neuro-Oncology 2014;16(Suppl. 1):i10
  • Burzynski, G., Burzynski, S.R., Janicki, T., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 in adult patients with recurrent glioblastoma multiforme based on protocol BT-21. NO-020. Neuro-Oncology 2013;15(Suppl. 3):iii103.
  • Burzynski, S., Janicki, T., Burzynski, G., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 in pediatric recurrent diffuse intrinsic pontine glioma. NO-021. Neuro-Oncology 2013;15(Suppl. 3):iii103.
  • Janicki, T., Burzynski, S., Burzynski, G., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 (ANP) in children with high-grade glioma (Protocol BT-06). NO-058. Neuro-Oncology 2013;15(Suppl. 3):iii112.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. A phase II study of Antineoplastons A10 and AS2-1 in children with brain tumors. Final report (Protocol BT-10). J Cancer Ther 2017; 8:173-187.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S. Antineoplastons A10 and AS2-1 in the treatment of children with optic pathway glioma. Final report for Protocol with BT-23. Cancer Clin Oncol 2017; 6(1):25-35.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S. Primary CNS tumors and leptomeningeal, disseminated and/or multicentric disease in children treated in phase II studies with antineoplastons A10 and AS2-1. Cancer Clin Oncol 2016; 5(2):38-48.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S. A phase II study of antineoplastons A10 and AS2-1 in children with low-grade astrocytomas-Final report (Protocol BT-13). J Cancer Ther 2016; 7(12):837-850.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S. Comprehensive genomic profiling of recurrent classic glioblastoma in a patient surviving eleven years following antineoplaston therapy. Cancer Clin Oncol 2015; 4(2):41-52.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S. A phase II study of antineoplastons A10 and AS2-1 in adult patients with primary brain tumors-Final report (Protocol BT-09). J Cancer Ther 2015; 6(12):1063-1074.
  • Burzynski, S.R., Janicki, T.J., Weaver, R.A., Szymkowski, B.G., Khan, M.I., Dolgopolov, V. Treatment of multicentric brainstem gliomas with antineoplastons (ANP) A10 and AS2-1. Neuro-Oncology. 2006;10:466.
  • Weaver, R.A., Burzynski, S.R., Janicki, T.J., Burzynski, B., Jurida, G., Szymkowski, B. Long-term survival in patients with glioblastoma multiforme treated in phase II studies with ANP. Neuro-Oncology 2005;7:299.
  • Burzynski, S.R., Weaver, R.A., Janicki, T., Szymkowski, B., Jurida, G., Khan, M., Dolgopolov, V. Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with Antineoplastons A10 AS2-1.
  • Burzynski, S.R., Weaver, R. Bestak. M., Lewy R.I., Janicki, T., Jurida, G., Szymkowski, B., Khan, M., Dolgopolov, V. Long-term survivals in phase II studies of Antineoplastons A10 and AS2-1 (ANP) in patients with diffuse intrinsic brain stem glioma. Neuro-Oncology 2004;6:386.
  • Burzynski, S.R., Weaver, R. Bestak. M., Janicki, T., Szymkowski, B., Jurida, G., Khan, M., Dolgopolov, V. Treatment of primitive neuroectodermal tumors (PNET) with antineoplastons A10 and AS2-1 (ANP). Preliminary results of phase II studies. Neuro-Oncology 2004;6:428.
  • Burzynski, S.R., Weaver, R. Bestak. M., Janicki, T., Jurida, G., Szymkowski, B., Khan, M., Dolgopolov, V. Phase II studies of antineoplastons A10 and AS2-1 (ANP) in children with atypical teratoid/rhabdoid tumors (AT/RT) of the central nervous system. A preliminary report. Neuro-Oncology 2004;6:427.
  • Burzynski, S.R., Weaver, R., Lewy. R., Janicki, T., Jurida, G., Szymkowski, B., Khan, M., Bestak, M. Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma. A Preliminary Report. Drugs R&D 2004;5(6):315-326.
  • Burzynski, S.R., Conde, A.B., Peters, A., Saling B., Ellithorpe, R., Daugherty, J.P., and Nacht, C.H. A Retrospective Study of Antineoplastons A10 and AS2-1 in Primary Brain Tumors. Clin. Drug Invest 1999;18:1-10.
  • Burzynski, S.R., Kubove, E., Burzynski, B., Phase II clinical trials of antineoplastons A10 and AS2-1 infusions in astrocytoma. Recent Advances in Chemotherapy. Adam D. (Ed), Futuramed Publishers. 1992; Munich, Germany.
  • Burzynski, S.R., Kubove, E., Burzynski, B., Phase I clinical studies of oral formulation of antineoplaston AS2-1. Adv Exptl Clin Chemother 1988;2:29-36.
  • Burzynski, S.R. Treatment of malignant brain tumors with antineoplastons. Adv Exptl Clin Chemother 1988;6:45-56.
  • Burzynski, S.R., Kubove, E. Initial clinical study with antineoplaston A2 injections in cancer patients with five years follow-up. Drugs Exptl Clin Res 1987;13 (suppl 1):1-12.
  • Burzynski, S.R., Kubove, E. Phase I clinical studies of antineoplaston A3 injections. Drugs Exptl Clin Res 1987;13 (suppl 1):17-29.
  • Burzynski, S.R., Kubove, E., Burzynski, B. Phase I clinical studies of antineoplaston A5 injections. Drugs Exptl. Clin Res 1987;13 (suppl 1):37-43.
  • Burzynski, S.R., Kubove, E. Toxicology studies of antineoplaston A10 injections in cancer patients. Drugs Exptl Clin Res 1986;12 (suppl 1):47-55.
  • Burzynski, S.R. Toxicology studies of antineoplaston AS2-5 injections in cancer patients. Drugs Exptl Clin Res 1986;12 (suppl 1):17-24.
  • Burzynski, S.R., Burzynski, B., Mohabbat, M.O. Toxicology studies of antineoplaston AS2-1 injections in cancer patients. Drugs Exptl Clin Res 1986;12 (suppl):25-35.
  • Burzynski, S.R. Phase I clinical studies of antineoplaston AS2-5 injections. Recent Advances in Chemotherapy. Ishigami J. (Ed), University of Tokyo Press.
  • Burzynski, S.R., Mohabbat, M.O., Burzynski, B. Toxicology studies on oral formulation of antineoplaston A10 in cancer patients. Future Trends in Chemotherapy 1985;6:485-493.
  • Burzynski, S.R., Mohabbat, M.O., Burzynski, B. Human toxicology studies on oral formulation of antineoplaston A10. Drugs Exptl Clin Res 1984;10:891-909.
  • Burzynski, S.R., Mohabbat, M.O., Burzynski, B. Toxicology studies on oral formulation of antineoplaston A10 in cancer patients. Drugs Exptl Clin Res 1984;10:611-619.
  • Burzynski, S.R., Stolzmann, Z., Szopa, B., Stolzmann, E., Kaltenberg, O.P. Antineoplaston A in cancer therapy (I). Physiol Chem Phys 1977;9:485-500.

Case Reports

  • Janicki, T.J., Burzynski, G.S., Burzynski, S.R. Long-term survival (over 15 years) of pathologically confirmed recurrent glioblastoma multiforme: A case report. AT-28. Neuro Oncol 2014;16(Suppl. 5):v14-15.
  • Burzynski, G.S., Janicki, T.J., Marszalek, A., Burzynski, S.R. Long-term survival (>20 years) of a child with brainstem glioma treated with antineoplastons A10 and AS2-1: A case report. PT-02. Neuro Oncol 2014;16(Suppl. 5):v175.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. Long-term survival (> 13 years) in a child with recurrent diffuse pontine gliosarcoma: the case report. Journal of Pediatric Hematology/Oncology 2014;36(7):e433-e439. doi: 10.1097/MPH.0000000000000020.
  • Burzynski, G., Janicki, T., Burzynski, S.R., Marszalek, A. Long-term survival (over 20 years) and pathologically confirmed complete response in pediatric anaplastic astrocytoma: a case report. HG-017. Neuro-Oncology 2014;16(Suppl. 1):i44.
  • Janicki, T., Burzynski, S.R., Burzynski, G., Marszalek, A. Long-term survival (over 20 years), complete response and normal childhood development in medulloblastoma (PNET) without recurrence: a case report. MB-039-020. Neuro-Oncology 2014;16(Suppl. 1):i80.
  • Burzynski, S., Janicki, T., Burzynski, G., Marszalek, A. Long-term survival (over 13 years) in a child with recurrent diffuse pontine gliosarcoma: A case report. NO-089. Neuro-Oncology 2013;15(Suppl. 3):iii120.
  • Burzynski, S.R., Burzynski, G.S., Marszalek, A., Janicki, T.J., Martinez-Canca. J.F. Long-term survival over 21 years and pathologically confirmed complete response in pediatric anaplastic astrocytoma: A case report. J. Neurol Stroke 2015;2(6):00072.
  • Burzynski, S.R., Burzynski, G.S., Marszalek, A., Janicki, T.J., Martinez-Canca. J.F. Long-term survival (over 20 years), complete response and normal childhood development in medulloblastoma treated with antineoplastons A10 and AS2-1. J. Neurol Stroke 2015;2(3):00054.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. Complete response and long-term survival (>20 years) of a child with tectal glioma: A case report. Pediatr Neurosurg 2015;50(2):99-103.
  • Burzynski, S.R., Burzynski, G.S., Brookman, S. A case of sustained objective response of recurrent/progressive diffuse intrinsic pontine glioma with phenylbutyrate and targeted agents. J Cancer Ther 2015; 6:40-44.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. Long-term survival (>13 years) in a child with recurrent diffuse pontine gliosarcoma: the case report. Journal of Pediatric Hematology/Oncology 2014;36(7):e433-e439. doi:10.1097/MPH.0000000000000020.
  • Burzynski, S.R., Nagy-Kubove, E. Treatment of esthesioneuroblastoma and non-small cell lung cancer with phenylbutyrate. Journal of Cancer Therapy 2011;2:518-522.
  • Burzynski, S.R., Marquis, A., Nagy-Kubove, E., Janicki, T.J. Successful treatment of recurrent triple-negative breast cancer with combination of targeted therapies. Journal of Cancer Therapy 2011;2:372-376.
  • Weaver, R.A., Szymkowski, B., Burzynski, S.R. Over a 10-year survival and complete response of a patient with diffuse intrinsic brainstem glioma (DBSG) treated with antineoplastons (ANP). Neuro-Oncology 2009;11:923.
  • Burzynski, S.R. Recent clinical trials in diffuse intrinsic brainstem glioma. Cancer Therapy 2007;5, 379-390.
  • Burzynski, S.R., Weaver, R., Szymkowski, B. A case report of a complete response and 20-year survival of a patient with a recurrent diffuse intrinsic brainstem anaplastic astrocytoma. Neuro-Oncology 2007;9:536.
  • Burzynski, S.R., Weaver, R.A., Szymkowski, B., Janicki, T.J., Khan, M.I., Dolgopolov, V. Complete response of a diffuse intrinsic brainstem tumor and von Hippel Lindau (VHL) disease to antineoplastons A10 and AS2-1 (ANP): a case report. Neuro-Oncology. 2006;10:439.
  • Burzynski, S.R., Weaver, R.A., Janicki, T.J., Burzynski B., Jurida, G. Targeted therapy with ANP in children less than 4 years old with inoperable brain stem gliomas. Neuro-Oncology 2005;7:300.
  • Burzynski, S.R., Lewy, R.I., Weaver, R., Janicki, T., Jurida, G., Khan, M., Larisma, C.B., Paszkowiak, J., Szymkowski, B. Long-term survival and complete response of a patient with recurrent diffuse intrinsic brain stem glioblastoma multiforme. Integrative Cancer Therapies 2004;3:257-261.

Review Articles

  • Burzynski, S.R. Stanislaw R. Burzynski, MD, PhD: Novel cancer research and the fight to prove its worth. Alternative Therapies in Health and Medicine 2012;18(3):54-61.
  • Burzynski, S.R. The coming pandemic of liver cancer: In search of genomic solutions. In: American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics, Volume XI;2009.
  • Burzynski, S.R. Genomic approach to cancer treatment. In: American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics, Volume X;2008;37-44. 
  • Burzynski, S.R. Treatments for Astrocytic Tumors in Children: Current and Emerging Strategies. Pediatric Drugs 2006;8:167-178.
  • Burzynski, S.R. Janicki, T.J., Weaver, R.A., Burzynski, B. Targeted therapy with Antineoplastons A10 and AS2-1 of high grade, recurrent and progressive brainstem glioma. Integrative Cancer Therapies 2006; 5(1):40-47.
  • Burzynski S.R. The Present State of Antineoplaston Research. Integrative Cancer Therapies 2004;3:47-58.
  • Burzynski, S.R. Antineoplastons. In: Clinician’s Complete Reference To Complementary/Alternative Medicine, Novey, D.W. (Ed.). Mosby 2000;496-507, St. Louis, USA.
  • Burzynski, S.R. Antineoplastons in the treatment of malignant brain tumors. Anti-Aging Medical Therapeutics, vol. 2. Klatz RM. Goldman R. (Ed), Health Quest Publications 1998;28-34, Marina del Rey, Ca, USA.
  • Burzynski, S.R. Potential of antineoplastons in diseases of old age. Drugs & Aging 1995;7:157-167.
  • Burzynski, S.R. Antineoplastons, An Investigational Cancer Therapy. Townsend Letter for Doctors 1993;3,150-153.
  • Burzynski, S.R. Novel differentiation inducers. Recent Advances in Chemotherapy. Adam D. (Ed), Futuramed Publishers. 1992; Munich, Germany.
  • Burzynski, S.R., Kubove, E., Burzynski, B. Treatment of hormonally refractory cancer of the prostate with antineoplaston AS2-1. Drugs Exptl Clin Res 1990;16:361-369.
  • Burzynski, S.R. Isolation, purification and synthesis of antineoplastons. Internat J Exptl Clin Chemother 1989;2:63-69.
  • Burzynski, S.R. Antineoplastons: Basic research and clinical applications. Adv Exptl Clin Chemother. 1988;2: 1-9.
  • Burzynski, S.R. Isolation, purification and synthesis of antineoplastons. Adv Exptl Clin Chemother. 1988;6: 1-7.
  • Burzynski, S.R. Antineoplastons A3. Drugs of the Future 1986;11:551-552.
  • Burzynski, S.R. Antineoplastons – History of the research (I). Drugs Exptl Clin Res 1986;12 (suppl 1):1-9.
  • Burzynski, S.R. Khalid, M. Antineoplaston AS2-5. Drugs of the Future 1986;11:364-365.
  • Burzynski, S.R. Khalid, M. Antineoplaston AS2-1. Drugs of the Future 1986;11:361-363.
  • Burzynski, S.R. Antineoplaston A2. Drugs of the Future 1986;11:549-550.
  • Burzynski, S.R. Antineoplaston A5. Drugs of the Future 1986;11:824-825.
  • Burzynski, S.R. Synthetic antineoplastons and analogs. Drugs of the Future 1986;11:679-688.
  • Burzynski, S.R., Hai TT. Antineoplaston A10. Drugs of the Future 1985;10:103-105.

Basic Science

  • Burzynski, S.R., Patil, S.S. The effect of antineoplastons A10 and AS2-1 and metabolites of sodium phenylbutyrate on gene expression in glioblastoma multiforme. J Cancer Ther 2014;5:929-945.
  • Aliev, G., Burzynski, G., Ashraf, G.M., Jabir, N.R., Cacabelos, R., Benberin, V.V., Burzynski, S.R. Implication of oxidative stress-induced oncogenic signaling pathways as a treatment strategy for neurodegeneration and cancer. SystBiol Free Rad Antioxid 2014; 2325-2347; DOI: 10.1007/978-3-642-30018-9.
  • Aliev, G., Palacios, H.H., Cacabelos, P., Cacabelos, R., Burzynski, G., Burzynski, S.R. Mitochondria specific antioxidants and their derivatives in the context of the drug development for neurodegeneration and cancer.  Drug Designing 2013;2(1):103.
  • Patil, S.S., Mrowczynski, E., Grela, K., Burzynski, S.R. Phenylacetylglutaminate in combination with phenylbutyrate effectively inhibits growth of brain tumor cells in vitro. Neuro-Oncology 2012;14(Suppl. 3):iii16.
  • Patil, S.S., Burzynski, S.R., Mrowczynski, E., Grela, K., Chittur, S.V. Phenylacetylglutaminate and phenylacetate in combination upregulate VDUP1, cause cell cycle blockade and apoptosis in U87 glioblastoma cells. Journal of Cancer Therapy 2012;3:192-200.
  • Burzynski, S.R., Patil, S.S. The effect of antineoplastons A10 and AS2-1 and metabolites of sodium phenylbutyrate on gene expression in glioblastoma multiforme. J. Cancer Ther 2014;5:929-945.
  • Patil, S.S., Burzynski, S.R., Mrowczynski, E., Grela, K., Chitur, S.V. Phenylacetylglutaminate and phenylacetate in combination upregulate VDUPI, cause cell cycle blockade and apoptosis in U87 glioblastoma cells, Journal of Cancer Therapy 2012;3:192-200.
  • Patil, S., Burzynski, S.R., Mrowczynski, E., Grela, K. CB-15. Targeting microRNAs in glioma cells with antineoplastons. Neuro-Oncology 2010;12(Suppl. 4):iv10.
  • Patil, S., Burzynski, S.R., Mrowczynski, E., Grela, K. Antineoplastons initiate caspase induced apoptosis by suppressing surviving expression in U87 glioblastoma cells. Neuro-Oncology 2010;12(6):ii87.
  • Patil, S., Burzynski, S., Chittur, S., Mrowczynski, E., Grela, K. The ingredients of antineoplaston AS2-1 down-regulate glycolysis pathways in glioblastoma cells. Neuro-Oncology 2008;10:1148.
  • Patil, S., Burzynski, S., Chittur, S., Mrowczynski, E., Grela, K. Antineoplaston AS2-1 affects cell cycle checkpoints, leading to apoptosis in human glioblastoma cells. Neuro-Oncology 2008;10:786.
  • Patil, S., Burzynski, S.R., Mrowczynski, E., Grela, K. Phenylacetylglutamine (PG) and Phenylacetate (PN) interact additively to produce detachment-induced apoptosis/anoikis in glioblastoma cells. Neuro-Oncology 2007;9:482.
  • Burzynski, S.R., Ilkowska-Musial, E., Klimczak M.W., Musial, L. Antineoplastons in Dairy Products. Journal of Applied Nutrition 2004;54;1-8.
  • Waldbillig R, Burzynski S.R. Mechanism of action, uptake, and gene array studies on the antineoplastic agent phenylacetylglutamine (PG) in human glioma cells U-87. Neuro-Oncology 2003;10:309.
  • Burzynski, S.R., Axler, M.L., Lewy, R.I., Janicki, Tomasz, Ilkowska-Musial, Elwira, Baranowska, Anna. Amino Acid Supplementation in Treatment of Cancer-Related Symptoms. Journal of Applied Nutrition 2003; 53:52-60.
  • Soltysiak-Pawluczuk, D., Burzynski, S.R., Feldo, M., Majewska, B., Kleinrok, Z. Cellular accumulation of antineoplaston AS2-1 in human hepatoma cells. Cancer Letters 88 (1995);88:107-112.
  • Juskiewicz, M., Chodkowska, A., Burzynski, S.R., Mlynarczyk, M., Kleinrok, Z. The influence of antineoplaston A5 on particular subtypes of central dopaminergic receptors. Drugs Exptl Clin Res 1995;21:153-156.
  • Juskiewicz, M., Chodkowska, A., Burzynski, S.R., Feldo, M., Majewska, B., Kleinrok, Z. The influence of antineoplaston A5 on the central dopaminergic structures. Drugs Exptl Clin Res 1994;20:161-167.
  • Liau, M.C., Liau, C.P., Burzynski, S.R. Potentiation of induced terminal differentiation by phenylacetic acid and related chemicals. Internat J Exptl Clin Chemother 1992;5:9-17.
  • Liau, M.C., Luong, Y., Liau, C.P., Burzynski, S.R. Prevention of drug induced DNA hypermethylation by antineoplaston components. Internat J Exptl Clin Chemother 1992;5:19-27.
  • Lee, S.S., Burzynski, S.R. Synergistic Effect of Antineoplaston A5 and Retinoic Acid on the Induction of Human Promyelocytic Leukemia line HL-60. Recent Advances in Chemotherapy. Adam D. (Ed), Futuramed Publishers. 1992:Munich, Germany.
  • Liau, M.C., Luong, Y., Liau, C.P., Burzynski, S.R. Prevention of drug-induced DNA hypermethylation by antineoplastons. Recent Advances in Chemotherapy. Adam D. (Ed), Futuramed Publishers. 1992: Munich, Germany.
  • Lee, S.S., Burzynski, S.R. Antineoplaston A5: A growth inhibitor for cancerous cells and growth stimulator for normal cells. Internat J Exptl Clin Chemother 1991;4:63-65.
  • Kampalath, B.N., Liau, M.C., Burzynski, B., Burzynski, S.R. Protective effect of antineoplaston A10 in hepatcarcinogenesis induced by aflatoxin B1. Internat J Tissue Reactions 1990;12 (suppl):43-50.
  • Liau, M.C., Lee, S.S., Burzynski, S.R. Modulation of cancer methylation complex isoenzymes as a decisive factor in the induction of terminal differentiation mediated by antineoplaston A5. Internat J Tissue Reactions 1990;12 (suppl): 27-36.
  • Lee, S.S., Burzynski, S.R. Inducibility of HL-60 leukemic cells to undergo terminal differentiation after repeated treatment with antineoplaston A5. Internat J Exptl Clin Chemother 1990;3:125-128.
  • Lee, S.S., Burzynski, S.R. Induction of differentiation of HL-60 human promyelocytic leukemic cell by antineoplaston A5. Internat J Tissue Reactions 1990;12(suppl):37-42.
  • Liau, M.C., Ashraf, A.Q., Lee, S.S., Hendry, L.B., Burzynski, S.R. Riboflavin as a minor active anticancer component of antineoplaston A2 and A5. Internat J Tissue Reactions 1990;12:19-26.
  • Liau, M.C., Lee, S.S., Burzynski, S.R. Separation of active anticancer components of antineoplaston A2, A3, and A5. Internat J Tissue Reactions 1990;12 (suppl): 1-17.
  • Hendry, L.B., Muldoon, T.G., Burzynski, S.R. Modeling studies suggest the modified dipeptide analog phenylacetylamino-2, 6-piperidinedione may interact with DNA. Adv Exptl Clin Chemother. 1988;2:11-13.
  • Liau, M.C., Lee, S.S., Burzynski, S.R. Differentiation inducing components of antineoplaston A5. Adv Exptl Clin Chemother. 1988;6:9-25.
  • Lee, S.S., Burzynski, S.R. Terminal differentiation of HL-60 human promyelocytic leukemia cells induced by antineoplaston A2. Adv Exptl Clin Chemother 1988;6:27-31.
  • Ashraf, A.Q., Kampalath, B.N., Burzynski, S.R. Pharmacokinetic analysis of antineoplaston A10 injections following intravenous administration in rats. Adv Exptl Clin Chemother 1988;6:33-39.
  • Lee, S.S., Burzynski, S.R. Tissue culture and animal toxicity studies of antineoplaston A5. Drugs Exptl Clin Res 1987;13 (suppl 1): 31-35.
  • Kampalath, B.N., Liau, M.C., Burzynski, B., Burzynski, S.R. Chemoprevention by antineoplaston A10 of benzo (a) pyrene-induced pulmonary neoplasia. Drugs Exptl Clin Res 1987;13 (suppl 1): 51-55.
  • Lee, S.S., Mohabbat, M.O., Burzynski, S.R. In vitro cancer growth inhibition and animal toxicity studies of antineoplaston A3. Drugs Exptl Clin Res 1987;13 (suppl 1):13-16.
  • Khalid, M., Burzynski, S.R. N,N`-disubstituted L-isoglutamines as novel cancer chemotherapeutic agents. Drugs Exptl Clin Res 1987;13 (suppl):57-60.
  • Hendry, L.B., Muldoon, T.G., Burzynski, S.R., Copland, J.A., Lehner, A.F. Stereochemical modeling studies of the interaction of antineoplaston A10 with DNA. Drugs Exptl Clin Res 1987;13 (suppl 1):77-81.
  • Liau, M.C., Szopa, M., Burzynski, B., Burzynski, S.R. Quantitative assay of plasma and urinary peptides as an aid for the evaluation of cancer patients undergoing antineoplaston therapy. Drugs Exptl Clin Res 1987;13 (suppl 1):61-70.
  • Ashraf, A.Q., Liau, M.C., Kampalath, B.N., Burzynski, S.R. Pharmacokinetic study of radioactive antineoplaston A10 following oral administration in rats. Drugs Exptl Clin Res 1987;13 (suppl 1):45-50.
  • Burzynski, S.R., Mohabbat. M.O. Chronic animal toxicity studies of antineoplaston A2. Drugs Exptl Clin Res 1986;12 (suppl 1):73-75.
  • Ashraf, A.Q., Liau, M.C., Mohabbat, M.O., Burzynski, S.R. Preclinical studies of antineoplaston A10 injections. Drugs Exptl Clin Res 1986;12 (suppl 1):37-45.
  • Burzynski, S.R., Mohabbat, M.O., Lee, S.S. Preclinical studies of antineoplaston AS2-1 and antineoplaston AS2-5. Drugs Exptl Clin Res 1986;12 (suppl 1):11-16.
  • Liau, M.C., Burzynski, S.R. Altered methylation complex isoenzymes as selective targets for cancer chemotherapy. Drugs Exptl Clin Res 1986;12 (suppl 1):77-86.
  • Lehner, A.F., Burzynski, S.R., Hendry, L.B. 3-phenylacetylamino-2, 6-piperidinedione, a naturally occurring peptide analog with apparent antineoplastic activity may bind to DNA. Drugs Exptl Clin Res 1986;12 (suppl 1):57-72.
  • Lee, S.S., Mohabbat, M.O., Burzynski, S.R. Tissue culture and acute animal toxicity studies of antineoplaston A2. Future Trends in Chemotherapy 1985;6:481-484.
  • Burzynski, S.R., Mohabbat, M.O., Burzynski B. Animal toxicology studies on oral formulation of antineoplaston A10. Drugs Exptl Clin Res 1984;10:113-118.
  • Lee, S.S., Mohabbat, M.O., Burzynski, S.R. Tissue culture and animal toxicity studies of antineoplaston A2. Drugs Exptl Clin Res 1984;10:607-610.
  • Beall, P., Szopa, B., Burzynski, S.R., Hazlewood, C.F. Polypeptides that inhibit human breast cancer dell division. Cancer Biochem Biophys 1979;3:93-96.
  • Gross S, Galicka N, Grabarczyk M, Giannini M, Burzynski S.R., Stolzmann Z. Urinary Peptides inhibit DNA synthesis in vitro in certain cultured neoplastic cells. Clin Chem1977;23:148-149.
  • Gross, S., Galicka, N., Burzynski, S.R., Stolzmann, A. Urinary peptides in muscular dystrophy. Physiol Chem Phys 1976;8:161-166.
  • Burzynski, S.R. Sequential analysis in subnanomolar amounts of peptides; Determination of the structure of a habituation-induced brain peptide (ameletin) Anal Biochem 1976;70:359-365.
  • Burzynski, S.R., Loo, T.L., Ho, D.H., Rao, P.N., Georgiades, J., Kratzenstein, H. Biologically active peptides in human urine: III. Inhibitors of the growth of leukemia, osteosarcoma and HeLa cells. Physiol Chem Phys 1976;8:13-22.
  • Burzynski, S.R., Rao, P.N., Gross, S., Stolzman, Z. Inhibition of the Growth of HeLa Cells by the Peptide Isolated from Normal Human Urine. Fed Proc 1976;35:623.
  • Burzynski, S.R. Quantitative analysis of amino acids and peptides in the femtomolar range. Anal Biochem 1975;65:93-99.
  • Burzynski, S.R., Ungar, A.L., Lubanski, E. Biologically active peptides in human urine: II. Effect on intestinal smooth muscle and heart. Physiol Chem Phys 1974;6:457-468.
  • Burzynski, S.R., Ungar, A.L., Lubanski, E. Effect of Urinary Peptides on Smooth Muscle and Heart. Fed Proc 1974;33:547.
  • Burzynski, S.R. Biologically active peptides in human urine: I. Isolation of a group of medium-sized peptides. Physiol Chem Phys 1973;5:437-447.
  • Burzynski, S.R., Georgiades, J. Effect of Urinary Peptides on DNA, RNA and Protein Synthesis in Normal and Neoplastic Cells. Fed Proc 1973;32:766.

Theoretical Articles

  • Burzynski, S.R., Burzynski, G.S., Janicki, T.J. Recurrent glioblastoma multiforme, a strategy for long-term survival. J Cancer Ther 2014;5:957-976.
  • Burzynski, S.R. Gene Silencing – A New Theory of Aging. Med Hypoth 2003;60:578-583.
  • Burzynski, S.R. Immunosurveillance versus chemosurveillance. Post Nauk Med 1993;6:260-262.
  • Burzynski, S.R. Antineoplastons: Biochemical defense against cancer. Physiol Chem Phys 1976;8:275-279.

Books

  • Burzynski, S.R. Targeted Therapy for Brain Tumors. Columbus F, ed. Brain Cancer Therapy and Surgical Interventions. New York (NY); Nova Science Publishers, Inc. 2006;77-111.
  • Burzynski, S.R. Age Management Treatments Which Target Silenced Genes. Redberry GW, ed. Gene Silencing: New Research. Nova Science Publishers, Inc. 2006.
  • Burzynski, S.R. The Methylation Control of Gene Activation and Silencing Theory. The Basic Principles and Practice of Anti-Aging Medicine & Age Management for the Aesthetic Surgeon and Physician. Vincent C. Giampapa (Ed.) 2003;33-4.

Request an Appointment